Adenovirus Type 5 SARS-CoV-2 Vaccines Delivered Orally or Intranasally Reduced Disease Severity and Transmission in a Hamster Model

Investigators demonstrated that hamsters vaccinated by the oral or intranasal route with an adenovirus type 5-vectored SARS-CoV-2 vaccine candidate had robust and cross-reactive antibody responses.